Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs. Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.
1.1 Companion Diagnostics: The Bigger Picture
1.2 Research Focus: Advancing New Diagnostics and Therapeutics
1.3 Research Scope: Unveiling Novel Diagnostics Pathways
1.4 Analysis Framework: Frost & Sullivan’s Core Value
1.5 Research Methodology: Five Steps toward Success
2.1 Key Elements of Analysis: The ‘Companion Diagnostics’ Concept
2.2 Brief Overview of Companion Diagnostics
2.3 Effectiveness and Performance Validation for CDx
2.4 Overall Landscape of Cancer Companion Diagnostics
2.5 Precision Oncology Accelerated Pathway
2.6 Biomarker Stratification for Companion Diagnostics
2.7 Emerging Opportunities for Companion Diagnostics
3.1 Technology Synergy Reshaping Value Chain
3.2 Product Development and Commercialization
3.3 Technology and Business Landscape: Accelerators
3.4 Technology and Business Landscape: Challenges
3.5 New Approaches Driving Companion Diagnostics Solutions
4.1 Market Dynamics and Opportunities
4.2 Market Potential: Technology Focus Segmentation
4.3 Market Potential: Therapeutic Area and Regional Segmentation
4.4 Impact of Companion Diagnostics on Therapeutic Areas
4.5 Prominent Pharmaceutical Market Leaders
5.1 The Role of Stakeholders in Business Strategy
5.2 Technology Transfer Assessment and Perceptions
5.3 Disruptive Companion Diagnostics Solutions
5.4 Business Model Hybridization
5.5 Overall Environmental Impact Factors
5.6 Future Perspective for Companion Diagnostics
6.1 Key Funding and Investment Opportunities
6.2 Funding and Investment Models and Adoption
6.3 Funding Long Shots, Securitization, and Credit
6.4 Strategic Collaborations
7.1 Multicriteria Approach for Benchmarking
7.2 Strategic Portfolio Assessment
7.3 Level 1 Criteria: Innovation Development
7.4 Level 1 Criteria: Financial Performance
7.5 Level 1 Criteria: Market Evolution
7.6 Level 2 Criteria: Key Actions for Success
7.7 Analytic Performance Results
7.8 Multicriteria Final Assessment
7.9 Strategic Imperatives: Critical Success Factors
8.1 Key Industry Influencers
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
Legal Disclaimer
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs. Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Cecilia Van Cauwenberghe |
| Industries | Healthcare |
| WIP Number | D83E-01-00-00-00 |
| Is Prebook | No |
| Ti Codes | D901,D910,D913,D91A,D933,D935,D936,D937,D947-TI |
Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine
Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine
Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy
RELEASE DATE
13-Nov-2018
13-Nov-2018
REGION
Global
Global
Deliverable Type
Technology Research
Technology Research
Research Code: D83E-01-00-00-00
SKU: HC03104-GL-TR_22527
$4,950.00
In stock
SKU
HC03104-GL-TR_22527
Similar Research
Check items to add to the cart or
